

1633

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))		Docket No. 3115.00017
In Re Application Of: John Hadden		#5/100 08.21.02
Serial No. 10/015,123	Filing Date 10/26/01	Examiner unknown
Title: VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS		Group Art Unit 1633

RECEIVED  
JUN 13 2002  
TECH CENTER 1600/2900

Address to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.  
3115.00017

In Re Application: John Hadden



Examiner

Group Art Unit  
**RECEIVED**

Serial No.  
10/015,123

Filing Date  
10/26/01

JUN 13 2002

TECH CENTER 1600/2900

**VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))  
is attached.

- ☐ A check in the amount of \_\_\_\_\_
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 11-1449 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Angel Webb

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Signature

Kenneth I Kohn, Reg. No. 30,955  
KOHN & ASSOCIATES  
30500 Northwestern Highway  
Suite 410  
Farmington Hills, MI 48334

Dated: June 5, 2002

CC:



# MANUAL OF PATENT EXAMINING PROCEDURE

PTO/SB/08 (2-92)

Sheet 1 of 6

Form PTO-1449


## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)  
3115.00017Application Number  
10/015123Applicant  
John HaddenFiling Date  
10/26/01Group Art Unit  
1633
**RECEIVED**  
 JUN 13 2002  
 TECH CENTER 1600/2900

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
						11/17/72
	4,036,953	07/19/77	Adam et al.			01/23/78
	4,116,951,	09/26/78	Wang			03/24/80
	4,353,821	10/12/82	Birr et al.			03/26/81
	4,390,623	06/28/83	Frabricius et al.			03/18/82
	4,439,196	03/27/84	Higuchi			09/20/82
	4,447,224	05/08/84	DeCant, Jr. et al.			07/30/82
	4,447,233	05/08/84	Mayfield			05/24/82
	4,454,355	06/12/84	Schubert et al.			07/29/82
	4,466,918	08/21/84	Birr et al.			03/25/80
	4,470,926	09/11/84	Birr et al.			03/06/81
	4,475,196	10/02/84	LaZor			06/08/83
	4,486,194	12/04/84	Ferrara			11/26/82
	4,487,603	12/11/84	Harris			04/02/84
	4,612,365	09/16/86	Birr et al.			06/26/86
	4,910,296	03/20/90	Birr et al.			04/01/87
	4,925,678	05/15/90	Ranney			05/22/86
	4,959,217	09/25/90	Sanders et al.			06/30/89
	5,100,664	03/31/92	Doyle et al.			12/14/89
	5,167,616	12/01/92	Haak et al.			
	5,169,383	12/08/92	Gyory et al.			
	5,225,182	07/06/93	Sharma			10/31/91



	5,376,369	12/22/94	Allison et al.			02/08/90
	5,503,841	04/02/96	AS et al.			02/24/89
	5,632,983	05/27/97	Hadden			11/17/94
	5,643,565	07/01/97	Doyle et al.			09/09/95
	5,679,356	10/21/97	Bonnem et al.			07/07/93
	5,698,194	12/16/97	Hadden			02/29/96
	5,747,024	05/05/98	Grabstein et al.			07/19/95
	5,800,810	09/01/98	Doyle et al.			10/17/96
	5,849,307	12/15/98	Metz et al.			03/26/97
	6,017,537	01/25/00	Alexander et al.			12/18/98
	6,060,068	05/09/00	Doyle et al.			08/31/98

RECEIVED

JUN 13 2002

TECH CENTER 1600/2900

### FOREIGN PATENT DOCUMENTS

DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO



### OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

	Albert et al, "letter to nature", Nature, Vol. 392, pp.86-89, 1998.
	Barrera J, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. "Combination immunotherapy of squamous cell head and neck cancer: A phase II trial", Arch Otolaryngol Head Neck Surg 126:345-351, 2000.
	Bellone et al. "Cancer immunotherapy: synthetic and natural peptides in the balance", Immunology Today, Vol 20, No. 10, p 457-462, 1999
	Berd D, Mastrangelo MJ. "Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T suppressor function without depletion of the CD8+subset", Cancer Research 47:3317-3321, 1987.
	Berd D. "Low doses of chemotherapy to inhibit suppressor T cells", Progress in Clin Biol Res 288:449-458, 1989.
	Borysiewickz LK, Fiander A, Nimako M., Man, S., Wilkinson, GW., Westmoreland, D., Evans, AS., Adams, M., Stacey, SN., Boursnell, ME., Rutherford, E., Hickling, JK., Inglis, SC. "A recombinant vaccine virus encoding human papillomavirus type 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer", Lancet 347: 1524-1527, 1996.
	Burke and Olson, Methods in Enzymology, Vol. 194, "Preparation of Clone Libraries in Yeast Artificial-Chromosome Vectors", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 17, pp. 251-270, 1991.
	Capecchi, MR. "Altering the genome by homologous recombination", Science 244:1288-1292, 1989.
	Cortesina G, DeStefani A, Galcazzi E. "Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low dose but not a high dose of recombinant interleukin 2 injected perilymphatically", Br J Cancer 69:572-577, 1994.



RECEIVED  
RECEIVED  
JUN 11 2002  
RESEARCH & TRADE MARK OFFICE


		Cortesina G, DeStefani M, et al. "Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 administered perilymphatically", Cancer 62:2482-2485, 1988.
		Cregg JM, Vedvick TS, Raschke WC. "Recent Advances in the Expression of Foreign Genes in <i>Pichia pastoris</i> ", BioTechnology 11:905-910, 1993.
Will submit upon receipt		Culver. "Site-Directed recombination for repair of mutations in the human ADA gene", (Abstract) Antisense DNA & RNA based therapeutics, February, 1998, Coronado, CA.
		Davies, NP., Rosewell, IR., Brüggemann, M. "Targeted alterations in yeast artificial chromosomes for interspecies gene transfer", Nucleic Acids Research, Vol. 20, No. 11, pp. 2693-2698, 1992.
		Deans JP., Boyd AW., Pilarski LM., Transitions from High to Low Molecular Weight Isoforms of CD45 (T200) Involve Rapid Activation of Alternate mRNA Splicing and Slow Turnover of Surface CD45R, The Journal of Immunology, 143:1233-1238, No. 4, August 15, 1989.
		Deans JP., Shaw J., Pearse MJ., Pilarski LM., CD45R as a Primary Signal Transducer Stimulating IL-2 and IL-2R mRNA Synthesis by CD3 <sup>+</sup> 4 <sup>+</sup> Thymocytes, The Journal of Immunology, 143:2425-2430, No. 8, October 15, 1989.
		Dallal, RM., Lotze, MT. The dendritic cell and human cancer vaccines, Current Opinion In Immunology 2000, Vol. 12, pp. 583-588.
		Dickinson, P., Kimber, WL., Kilanowski, FM., Stevenson, B.J., Porteous, DJ., Dorin, JR. "High frequency gene targeting using insertional vector", Human Molecular Genetics, Vol. 2, No. 8, pp. 1299-1302, 1993.
		Duff and Lincoln. "Insertion of a pathogenic mutation into a yeast artificial chromosome containing the human APP gene and expression in ES cells", Research Advances in Alzheimer's Disease and Related Disorders, 1995.
		Gilboa E, Eglitis MA, Kantoff PW, Anderson WF. "Transfer and expression of cloned genes using retroviral vectors", BioTechniques 4(6):504-512, 1986.
Will submit upon receipt		Gillis S. et al., J. Immunology 120:2027-2032, 1978.
Will submit upon receipt		Hadden J. et al., Immunopharmacology, JAMA, 268:20:2964-2969, 1992.
		Hadden JW. "T-Cell Adjuvants", Int. J. Immunopharmac., Vol. 16, No. 9, pp. 703-710, 1994.
		Hadden JW, Endicott J, Baekey P, Skipper P, Hadden EM. "Interleukins and contrasuppression induce immune regression of head and neck cancer", Arch otolaryngol Head Neck Surg. 120:395-403, 1994.
		Hadden JW, Shah AR, Sosa M, Hadden EM. "Immunotherapy with natural interleukins and/or Thymosin $\alpha_1$ potentially augments T lymphocyte responses of hydrocortisone-treated aged mice", Int'l J Immunopharmacol 17:821-828, 1995.
		Hadden JW. "The immunology and immunotherapy of breast cancer: An update", Int'l J Immunopharmacol 21: 79-101, 1999.
		Hadden JW. "The immunopharmacology of head and neck cancer: An update", Int'l J Immunopharmacol 11/12:629-644, 1997.
		Hadden JW. "The treatment of zinc deficiency is an immunotherapy", Int'l J Immunopharmacol 17:696-701, 1995.
		Hank JA., Albertini, MR., Sondel, PM. "Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease", Cancer Chemother & Biol Resp Mod 18:210-222, 1999.



RECEIVED

JUN 13 2002


	Huston, J., Mudd, J., Hunter, M., Tai, M., McCartney, J., Warren, F., Haber, E., Oppermann, H. "Protein engineering of single-chain Fv antibodies and fusion proteins" Methods in Enzymology (JJ Langone, ed.; Academic Press, New York, NY) 203:46-88, 1991.
	Huxley, C., Hagino, Y., Schlessinger, D., Olson, MV. "The human HPRT gene on a yeast artificial chromosome is functional when transferred to mouse cells by cell fusion", Genomics, 9:742-750 1991.
	Jakobovits, A., Moore, AL., Green, LL., Vergara, GJ., Maynard-Currie, CE., Austin, HA., Klapholz, S. "Germ-line transmission and expression of a human-derived yeast artificial chromosome", Nature, Vol. 362, pp. 255-261, 1993.
	Johnson, S., Bird, RE. "Construction of single-chain Fv derivations of monoclonal antibodies and their production of <i>Escherichia coli</i> ", Methods in Enzymology (JJ Langone, ed.; Academic Press New York, NY) 203:88-99, 1991.
	June CH., Ledbetter JA., Lindsten T., Thompson CB., Evidence for the Involvement of Three Distinct Signals in the Induction of IL-2 Gene Expression in Human T Lymphocytes, The Journal of Immunology, 143:153-161, No. 1, July 1, 1989.
	Kavanaugh DY., Carbone DP. "Immunologic dysfunction in cancer", Hematol-Oncol Clinics of North Amer 10(4):927-951, 1996.
	Lamb et al. "Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice", Nature Genetics, Vol. 5, pp. 22-29, 1993.
	Maass G, Schmidt W, Berger M, et al. "Priming of tumor-specific T-cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination", Proc Nat'l Acad Sci USA, 92:5540-5542, 1995.
	Mackall, CL. "T-Cell Immunodeficiency Following Cytotoxic Antineoplastic Therapy: A Review", Stem Cells 2000, Vol. 18, pp10-18, 1999.
	Mackall, CL., Fleisher, TA., Brown, MR., Andrich, MP., Chen, CC., Feuerstein, MD., Horowitz, ME., McGrath, IT., Shad, AT., Steinberg, SM., Wexler, LH., Gress, RE. Age, Thymopoiesis, and CD4+ T-Lymphocyte Regeneration After Intensive Chemotherapy, New England Journal of Medicine Vol. 332, pp. 143-149, 1995.
	Maclean, GD., Miles, DW., Rubens, RD., Reddish, MA., Longenecker, BM. Enhancing the effect of Theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide", J Immunother Emphasis Tumor Immunol 19(4):309-316, 1996.
	Marshak, DR., Kadonaga, JT., Burgess, RR., Knuth, MW., Brennan, WA. Jr., Lin, S. "Strategies for Protein Purification and Characterization. A laboratory course manual", CSHL Press, 1996.
	Mastrangelo, MJ., Maguire, HC. Jr., Sato T., Nathan, FE., Berd, D. "Active specific immunization in the treatment of patients with melanoma", (Review) Seminars in Oncology 23(6):773-781, 1996.
	Meneses A, Verastrgui E, Barrera JL, Zinser J, de la Garza J, Hadden JW. "Historical findings in patients with head and neck squamos cell carcinoma receiving perilympathic natural cytokine mixture (IRX-2) prior to surgery", Arch Pathol Lab Med 122:447-454, 1998.
	Mernaugh and Mernaugh. "An overview of phage-displayed recombinant antibodies", Molecular Methods In Plant Pathology (RP Singh and US Singh, eds.; CRC Press Inc., Boca Raton, FL) pp. 359-365, 1995.
	Mishell, BB., Shiigi, SM. Selected Methods in Cellular Immunology, W.H. Freeman and Company, New York, 1981.



RECEIVED

JUN 12 2002

		Murphy GP, Tjio BA, Simmons SC, Jarisch SJ, Bowes VA, Ragde, H, Rogers M., Elgamal A, Kenny, GM, Cobb, OE, Ireton, RC, Troychak M, Salgaller M, Roitt I, AL., "Infusion of Dendritic Cells Pulsed With HLA-A2-Specific Prostate-Specific Membrane Antigen Peptides: A Phase II Prostate Cancer Vaccine Trial Involving Patients With Hormone-Refractory Metastatic Disease," The Prostate 38:73-78, Wiley-Liss, Inc. 1999.
		Pearson, BE., Choi, TK. "Expression of the human $\beta$ -amyloid precursor protein gene from a yeast artificial chromosome in transgenic mice", Proc. Natl. Acad. Sci. USA, 90:10578-82, 1993.
Will submit upon receipt		Riesenbeck et al., 1994.
Will submit upon receipt		Roitt I, Brostoff J, Male D. Immunology, C.V. Mosby Co. 1989.
		Rothstein, R. "Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast", Methods in Enzymology, Vol. 194, "Guide to Yeast Genetics and Molecular Biology", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 19, pp. 281-301, 1991.
		Saha, A., Hadden, EM., Hadden, JW. "Zinc induces thymulin secretion from human thymic epithelial cells in vitro and augments splenocytes and thymocyte response in vivo", Int'l J Immunopharmacol 17:729-734, 1995.
		Sahin, U., Tureco, O., Pfreundschuh, M. "Serological identification of human tumor antigens", Curr Opin Immunol 9:709-715, 1997.
		Sanda, MG., Smith, DC., Charles, LG., Hwang, C., Pienta, KJ., Schlom, J., Milenic, D., Panicali, D., Monte, JE. "Recombinant vaccinia-PSA (Prostvac) can include a prostate-specific immune response in androgen-modulated human prostate cancer", Urology 52:2, 1999.
		Schedl, A., Montoliu, L., Kelsey, G., Schütz, G. "A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice", Nature, Vol. 362, pp. 258-261, 1993.
		Sprent, J., Tough, DF. "T Cell Death and Memory", Science, Vol. 293, pp. 245-248, July 13, 2001.
		Strauss, WM., Dausman, J., Beard, C., Johnson, C. Lawrence, JB., Jaenisch, R. "Germ line transmission of a yeast artificial chromosome spanning the murine $\alpha_1(I)$ collagen locus", Science, Vol. 259, pp. 1904-1907, 1993.
		Tagawa M. "Cytokine therapy for cancer", Current Pharmaceut Design 6(6):681-699, 2000.
		Valente G, DeStefani A, Jemma C, Giovarelli M, Geuna N, Cortesina G, Forni G, Palestro G. "Infiltrating leukocyte populations and T-lymphocyte subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant interleukin-2. A pathologic and immunophenotypic study", Modern Pathol 3(6):702-708, 1990.
		Van der Eynde JB., Van der Brugger, P. "T cell defined tumor antigens", Curr Opin Immunol 9:684-693, 1997.
		Verastegui E, Barrera JL, Zinzer J, Del Rio, R., Meneses A, De La Garza, J., Hadden JW. "A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer", Int'l J Immunopharmacol 11/12:619-627, 1997.



RECEIVED

	Verastegui, E., Hadden, E., Barrera, J. L., Meneses, A., Hadden, J. W. 2002. A natural cytokine mixture (IRX-2) and its interference with immune suppression induces immune mobilization and regression of head and neck cancer. <i>Immunopharmacol</i> 1999 No. 12 Supplement.
	Wang, RF., Rosenberg, SA. "Human tumor antigens for cancer vaccine development", <i>Immunologic Reviews</i> 170:85-100, 1999.
Will submit upon receipt	Webb et al., 1973.
	Weber, J. "Tumor vaccines", <i>Medscape Anthology</i> 3:2, 2000.
	Whiteside, TL., Letessier, E., Hirabayashi, H., Vitolo, D., Bryant, J., Barnes, L., Snyderman, C., Johnson, JT., Myers, E., Herberman, RB., Rubin, J., Kirkwood, JM., Vlock, DR. "Evidence for Local and Systemic Activation of Immune Cells by Peritumoral injections of Interleukin 2 in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck", <i>Cancer Res.</i> 53:5654-5662, 1993.
	Wolf, GT., Amendola, BE., Diaz, R., Lovett, EJ., Hammerschmidt, RM., Peterson, KA. Definite vs Adjuvant Radiotherapy, <i>Arch. Otolaryngol</i> , Vol. 111:716-725, 1985.
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

Patent and Trademark Office; U.S.

PTO/SB/ 08 (2-92)  
DEPARTMENT OF COMMERCE